Piper Jaffray has published a research report on Gilead Sciences GILD.
In the report, Piper Jaffray wrote, "Our call with Gilead's CEO John Martin PhD and EVP of R&D Norbert Bischofberger PhD provided insights into the HIV franchise and HCV development strategy. We are incrementally more confident in the ability of the Quad HIV pill to displace Atripla and enable Gilead to grow following expiration of Atripla patents
in 2021."
Piper Jaffray rated Gilead Sciences an Overweight with a price target of $53.00. Gilead Sciences closed Wednesday at $38.15.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in